SCHEMBL3071111

SCHEMBL3071111

Cc1nc(-c2ccc(OCCCCl)cc2)sc1C(=O)O

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TARBP2 Q15633 2/20 0.70
RAB9A P51151 4/20 0.63
SMN1; SMN2 Q16637 4/20 0.63
KDM4E B2RXH2 3/20 0.63
NPC1 O15118 1/20 0.63
POLB P06746 1/20 0.63
GAA P10253 3/20 0.62
PPARD Q03181 4/20 0.59
PPARA Q07869 4/20 0.59
XDH P47989 2/20 0.50
ALDH1A1 P00352 2/20 0.48
MAPT P10636 2/20 0.48
KMT2A Q03164 2/20 0.48
MEN1 O00255 1/20 0.48
ABCC4 O15439 1/20 0.47
ABCB11 O95342 1/20 0.47
PGR P06401 1/20 0.47
CHRM1 P11229 1/20 0.47
PDE4A P27815 1/20 0.47
BLVRB P30043 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3069938 0.88 TARBP2 (0.54) TARBP2RAB9ASMN1; SMN2KDM4ENPC1
SCHEMBL8867253 0.88 TARBP2 (0.67) TARBP2RAB9ASMN1; SMN2KDM4ENPC1
SCHEMBL8867803 0.84 TARBP2 (0.73) TARBP2RAB9ASMN1; SMN2KDM4ENPC1
SCHEMBL3070582 0.82 PPARD (0.60) PPARDPPARAKMT2AMEN1
SCHEMBL3419091 0.82 RAB9A (0.74) TARBP2RAB9ASMN1; SMN2KDM4ENPC1
SCHEMBL28412421 0.82 TARBP2 (1.00) TARBP2RAB9ASMN1; SMN2KDM4ENPC1
SCHEMBL8868422 0.82 PPARD (0.59) TARBP2RAB9ASMN1; SMN2KDM4ENPC1
SCHEMBL8868337 0.81 RAB9A (0.74) TARBP2RAB9ASMN1; SMN2KDM4ENPC1
SCHEMBL3074369 0.80 HRH3 (0.71) TARBP2SMN1; SMN2GAAPPARDPPARA
SCHEMBL8867232 0.79 TARBP2 (0.65) TARBP2RAB9ASMN1; SMN2KDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080275046-A1 Compounds Comprising an Oxazole or Thiazole Moiety, Processes for Making Them, and Their Uses UCB PHARMA, S.A. (BE) 2008-11-06 US claimed
EP-1866293-A1 COMPOUNDS COMPRISING AN OXAZOLE OR THIAZOLE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES UCB Pharma, S.A. (BE) 2007-12-19 EP claimed
WO-2006103045-A1 COMPOUNDS COMPRISING AN OXAZOLE OR THIAZOLE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES UCB PHARMA S.A. (BE) 2006-10-05 WO claimed
US-7790720-B2 Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses UCB PHARMA, S.A. (BE) 2010-09-07 US disclosed
US-7790720-B2 Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses UCB PHARMA, S.A. (BE) 2010-09-07 US disclosed
US-7790720-B2 Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses UCB PHARMA, S.A. (BE) 2010-09-07 US disclosed
US-20080275046-A1 Compounds Comprising an Oxazole or Thiazole Moiety, Processes for Making Them, and Their Uses UCB PHARMA, S.A. (BE) 2008-11-06 US disclosed
US-20080275046-A1 Compounds Comprising an Oxazole or Thiazole Moiety, Processes for Making Them, and Their Uses UCB PHARMA, S.A. (BE) 2008-11-06 US disclosed
US-20080275046-A1 Compounds Comprising an Oxazole or Thiazole Moiety, Processes for Making Them, and Their Uses UCB PHARMA, S.A. (BE) 2008-11-06 US disclosed
EP-1866293-A1 COMPOUNDS COMPRISING AN OXAZOLE OR THIAZOLE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES UCB Pharma, S.A. (BE) 2007-12-19 EP disclosed
WO-2006103045-A1 COMPOUNDS COMPRISING AN OXAZOLE OR THIAZOLE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES UCB PHARMA S.A. (BE) 2006-10-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275046-A1 Compounds Comprising an Oxazole or Thiazole Moiety, Processes for Making Them, and Their Uses OXER1, OXTR, OGFR TARBP2 4543/4885RAB9A 4232/4885SMN1; SMN2 4814/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.